Fremanezumab as a preventive treatment for episodic and chronic migraine

References

• Hargreaves R. New migraine and pain research. Headache. 2007 Apr;47(Suppl 1):S26–43. PubMed PMID: 17425708.
   PubMedGoogle Scholar
• Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017 May;57(Suppl 2):47–55. PubMed PMID: 28485848.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994 Oct;14(5):320–327. PubMed PMID: 7828188
   PubMed Web of Science ®Google Scholar
• Goadsby P. Neuropeptides and migraine–a useful biological marker? Cephalalgia. 1995 Oct;15(5):333–334. PubMed PMID: 8536290.
   Web of Science ®Google Scholar
• Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017 Apr;158(4):543–559. PubMed PMID: 28301400; PubMed Central PMCID: PMCPMC5359791.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013 Sep;53(8):1230–1244.. PubMed PMID: 23848260.
   PubMed Web of Science ®Google Scholar
• Kopruszinski CM, Xie JY, Eyde NM, et al. Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 2017 May;37(6):560–570. PubMed PMID: 27206958.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 Mar 11;350(11):1104–1110. PubMed PMID: 15014183.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 Dec 20;372(9656):2115–2123. PubMed PMID: 19036425.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 Apr;31(6):712–722. PubMed PMID: 21383045.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114–125. PubMed PMID: 23965396.
   PubMed Web of Science ®Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 Aug;36(9):887–898. PubMed PMID: 27269043.
   PubMed Web of Science ®Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96. PubMed PMID: 28948500; PubMed Central PMCID: PMCPMC5612904.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013 Jan;93(1):78–85. PubMed PMID: 23212108.
   PubMed Web of Science ®Google Scholar
• Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013 Nov;347(2):478–486. PubMed PMID: 23975906.
   PubMed Web of Science ®Google Scholar
• Glaser SS, Ueno Y, DeMorrow S, et al. Knockout of alpha-calcitonin gene-related peptide reduces cholangiocyte proliferation in bile duct ligated mice. Lab Invest. 2007 Sep;87(9):914–926. PubMed PMID: 17618297.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao H, Supowit SC, et al. Activation of the renin-angiotensin system in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. J Hypertens. 2004 Jul;22(7):1345–1349. PubMed PMID: 15201551.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015 Jun;79(6):886–895. PubMed PMID: 25614243; PubMed Central PMCID: PMCPMC4456121.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100–1107. PubMed PMID: 25297013.
   PubMed Web of Science ®Google Scholar
• Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the cgrp binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740. PubMed PMID: 29089894; PubMed Central PMCID: PMCPMC5651004.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425–434. PubMed PMID: 28460892.
   PubMed Web of Science ®Google Scholar
• Florencio LL, de Oliveira AS, Carvalho GF, et al. Cervical muscle strength and muscle coactivation during isometric contractions in patients with migraine: a cross-sectional study. Headache. 2015;55(10):1312–1322. Nov-Dec.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1091–1100. PubMed PMID: 26432181.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014 May;28(5):389–399.. PubMed PMID: 24638916.
   PubMed Web of Science ®Google Scholar
• Walter S, Alibhoy A, Escandon R, et al. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6(4):871–878. Jul-Aug. PubMed PMID: 24866108; PubMed Central PMCID: PMCPMC4171022.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Silberstein SD, et al. From LBR-101 to fremanezumab for migraine. CNS Drugs. 2018 Nov;32(11):1025–1037. PubMed PMID: 30311143.
   PubMed Web of Science ®Google Scholar
• Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008 Dec;155(7):1093–1103. PubMed PMID: 18776916; PubMed Central PMCID: PMCPMC2597266.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol. 2007 Mar;150(5):633–640. PubMed PMID: 17245362; PubMed Central PMCID: PMCPMC2189771.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia. 2014 Jun;34(7):483–492. PubMed PMID: 24366980.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014 Oct;34(12):968–976. PubMed PMID: 24662322.
   PubMed Web of Science ®Google Scholar
• Allen DM, Chen LE, Seaber AV, et al. Calcitonin gene-related peptide and reperfusion injury. J Orthop Res. 1997 Mar;15(2):243–248. PubMed PMID: 9167627.
   PubMed Web of Science ®Google Scholar
• Kallner G, Gonon A, Franco-Cereceda A. Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. Cardiovasc Res. 1998 May;38(2):493–499. PubMed PMID: 9709411.
   PubMed Web of Science ®Google Scholar
• Lynch JJ Jr., Detwiler TJ, Kane SA, et al. Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats. J Cardiovasc Pharmacol. 2010 Nov;56(5):518–525. PubMed PMID: 20729756.
   PubMed Web of Science ®Google Scholar
• Supowit SC, Ethridge RT, Zhao H, et al. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1169–75. PubMed PMID: 15879482.
   PubMed Web of Science ®Google Scholar
• Lynch JJ Jr., Regan CP, Edvinsson L, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010 May;55(5):518–521. PubMed PMID: 20164785.
   PubMed Web of Science ®Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010 Sep 1;334(3):746–752. PubMed PMID: 20573757.
   PubMed Web of Science ®Google Scholar
• Regan CP, Stump GL, Kane SA, et al. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther. 2009 Feb;328(2):571–578. PubMed PMID: 18997059.
   PubMed Web of Science ®Google Scholar
• Shen YT, Mallee JJ, Handt LK, et al. Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J Cardiovasc Pharmacol. 2003 Nov;42(5):656–661. PubMed PMID: 14576515.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008 Sep 9;71(11):848–855.. PubMed PMID: 18779513.
   PubMed Web of Science ®Google Scholar
• Chagas OF, Eckeli FD, Bigal ME, et al. Study of the use of analgesics by patients with headache at a specialized outpatient clinic (ACEF). Arq Neuropsiquiatr. 2015 Jul;73(7):586–592. PubMed PMID: 26200053.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: results of the American migraine prevalence and prevention (AMPP) study. Cephalalgia. 2007 Mar;27(3):220–229. PubMed PMID: 17263769.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921–936. PubMed PMID: 20487038.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017 Nov 30;377(22):2113–2122. PubMed PMID: 29171818.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo on prevention of episodic migraine: a randomized clinical trial. Jama. 2018;319(19):2113–2122.
   Web of Science ®Google Scholar
• Industries TP Teva announces positive topline phase iiib results with fremanezumab in adults with migraine who did not respond to multiple classes of preventive treatments. 2018. Available from: https://www.tevapharm.com/news/teva_announces_positive_topline_phase_iiib_results_with_fremanezumab_in_adults_with_migraine_who_did_not_respond_to_multiple_classes_of_preventive_treatments_12_18.aspx
   Google Scholar
• Gutman D, Hellriegel E, Aycardi E, et al. A phase i, open-label, single-dose safety, pharmacokinetic, and tolerability study of the sumatriptan iontophoretic transdermal system in adolescent migraine patients. Headache. 2016 Sep;56(8):1300–1309. PubMed PMID: 27474357.
   PubMed Web of Science ®Google Scholar
• Yeung PP, Aycardi E, Bigal ME, et al. Early onset of action with fremanezumab versus placebo for the preventive treatment of chronic migraine Y [abstract]. J Headache Pain. 2017;18(1,suppl 1):132.
   Google Scholar
• Silberstein SD, Rapoport AM, Loupe PS, et al. The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache. 2018 Nov 18 PubMed PMID: 30450545. DOI:10.1111/head.13446.
   Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1081–1090. PubMed PMID: 26432182.
   PubMed Web of Science ®Google Scholar
• VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: functional status on headache-free days. Neurology. 2018 Sep 18;91(12):e1152–e1165. PubMed PMID: 30120138; PubMed Central PMCID: PMCPMC6161555.
   PubMed Web of Science ®Google Scholar
• Underwood E. A shot at migraine. Science. 2016 Jan 8;351(6269):116–119.. PubMed PMID: 26744391.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Ho AP, Behm MO, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012 Mar;91(3):459–466. PubMed PMID: 22278333.
   PubMed Web of Science ®Google Scholar
• Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018 May;58(5):715–723. PubMed PMID: 29878340; PubMed Central PMCID: PMCPMC6001517.
   PubMed Web of Science ®Google Scholar